Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction

• Published in: Biomolecules (Basel, Switzerland) Switzerland), 2019-09, Vol.9 (9), p.469
• Main Authors: Sörensen, Nils A, Ludwig, Sebastian, Makarova, Nataliya, Neumann, Johannes T, Lehmacher, Jonas, Hartikainen, Tau S, Haller, Paul M, Keller, Till, Blankenberg, Stefan, Westermann, Dirk, Zeller, Tanja, Schofer, Niklas
• Format: Article
• Language: English
• Subjects: acute coronary syndrome; Aged; cardiovascular events; Female; Humans; Limit of Detection; Male; Middle Aged; Myocardial Infarction - diagnosis; Myocardial Infarction - metabolism; Patient Admission; Prognosis; Risk Assessment; Survival Analysis; troponin; Troponin I - metabolism
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom9090469

High-sensitivity troponin has proven to be a promising biomarker for the prediction of future adverse cardiovascular events. We aimed to assess the prognostic value of high-sensitivity troponin I (hs-TnI) on admission in patients with suspected acute myocardial infarction (AMI) analyzed by a novel (Singulex Clarity cTnI) and established hs-TnI assay (ARCHITECT STAT hs-TnI, Abbott). Hs-TnI was measured in a total of 2332 patients from two prospective cohort studies presenting to the emergency department with suspected AMI. The prognostic impact for overall and cardiovascular mortality of both hs-TnI assays was assessed in the total patient cohort as well as in the subgroups of patients with AMI ( = 518) and without AMI (non-AMI) ( = 1814). Patients presenting with highest hs-TnI levels showed higher overall and cardiovascular mortality rates compared to those with lower troponin levels, irrespective of the assay used. Both hs-TnI assays indicated association with overall mortality according to adjusted hazard ratio (HR) among the entire study population (HR for Singulex assay: 1.16 (95% CI 1.08-1.24) and HR for Abbott assay: 1.17 (95% CI 1.09-1.25)). This finding was particularly pronounced in non-AMI patients, whereas no association between hs-TnI and overall mortality was found in AMI patients for either assay. In non-AMI patients, both assays equally improved risk prediction for cardiovascular mortality beyond conventional cardiovascular risk factors. Hs-TnI is independently predictive for adverse outcomes in patients with suspected AMI, especially in the subset of patients without confirmed AMI. There was no difference between the established and the novel assay in the prediction of mortality.